These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 15150604

  • 1. Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy?
    Sainsbury R.
    Br J Cancer; 2004 May 04; 90(9):1733-9. PubMed ID: 15150604
    [Abstract] [Full Text] [Related]

  • 2. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
    Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L.
    Health Technol Assess; 2007 Jul 04; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
    [Abstract] [Full Text] [Related]

  • 3. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
    Gibson LJ, Dawson C, Lawrence DH, Bliss JM.
    Cochrane Database Syst Rev; 2007 Jan 24; (1):CD003370. PubMed ID: 17253488
    [Abstract] [Full Text] [Related]

  • 4. The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer.
    Hamilton A, Piccart M.
    Ann Oncol; 1999 Apr 24; 10(4):377-84. PubMed ID: 10370778
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
    Rose C.
    Am J Clin Oncol; 2003 Aug 24; 26(4):S9-16. PubMed ID: 12902872
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy.
    Brodie AH, Mouridsen HT.
    Am J Clin Oncol; 2003 Aug 24; 26(4):S17-26. PubMed ID: 12902873
    [Abstract] [Full Text] [Related]

  • 9. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M.
    Clin Ther; 2007 Aug 24; 29(8):1535-47. PubMed ID: 17919537
    [Abstract] [Full Text] [Related]

  • 10. Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer.
    Riemsma R, Forbes CA, Kessels A, Lykopoulos K, Amonkar MM, Rea DW, Kleijnen J.
    Breast Cancer Res Treat; 2010 Aug 24; 123(1):9-24. PubMed ID: 20535542
    [Abstract] [Full Text] [Related]

  • 11. A summary of second-line randomized studies of aromatase inhibitors.
    Buzdar AU.
    J Steroid Biochem Mol Biol; 2001 Dec 24; 79(1-5):109-14. PubMed ID: 11850214
    [Abstract] [Full Text] [Related]

  • 12. Challenges in the endocrine management of breast cancer.
    Mouridsen HT, Rose C, Brodie AH, Smith IE.
    Breast; 2003 Aug 24; 12 Suppl 2():S2-19. PubMed ID: 14659138
    [Abstract] [Full Text] [Related]

  • 13. Safety of aromatase inhibitors in the adjuvant setting.
    Perez EA.
    Breast Cancer Res Treat; 2007 Aug 24; 105 Suppl 1(Suppl 1):75-89. PubMed ID: 17912638
    [Abstract] [Full Text] [Related]

  • 14. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
    Gibson L, Lawrence D, Dawson C, Bliss J.
    Cochrane Database Syst Rev; 2009 Oct 07; 2009(4):CD003370. PubMed ID: 19821307
    [Abstract] [Full Text] [Related]

  • 15. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on letrozole or anastrozole. A phase II trial conducted by the Hellenic Group of Oncology (HELGO).
    Gennatas C, Michalaki V, Carvounis E, Psychogios J, Poulakaki N, Katsiamis G, Voros D, Kouloulias V, Mouratidou D, Tsavaris N.
    Tumori; 2006 Oct 07; 92(1):13-7. PubMed ID: 16683378
    [Abstract] [Full Text] [Related]

  • 16. A roundtable discussion of aromatase inhibitors as therapy for breast cancer.
    Allred DC, Baum M, Buzdar AU, Carlson RW, Dowsett M, Elledge RM, Gradishar WJ, Grana G, Howell A, Mamounas EP.
    Breast J; 2003 Oct 07; 9(3):213-22. PubMed ID: 12752630
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
    Howell A, Howell SJ, Clarke R, Anderson E.
    J Steroid Biochem Mol Biol; 2001 Dec 07; 79(1-5):227-37. PubMed ID: 11850229
    [Abstract] [Full Text] [Related]

  • 19. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors.
    Rugo HS.
    Ann Oncol; 2008 Jan 07; 19(1):16-27. PubMed ID: 17693420
    [Abstract] [Full Text] [Related]

  • 20. An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole.
    Rose C, Vtoraya O, Pluzanska A, Davidson N, Gershanovich M, Thomas R, Johnson S, Caicedo JJ, Gervasio H, Manikhas G, Ben Ayed F, Burdette-Radoux S, Chaudri-Ross HA, Lang R.
    Eur J Cancer; 2003 Nov 07; 39(16):2318-27. PubMed ID: 14556923
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.